Which is better, NBIX or PME.AX?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than NBIX — 78/100 (B grade) vs 66/100 (B). That said, "better" depends on which framework you trust — NBIX wins on none; PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy NBIX or PME.AX?

This page is an educational comparison, not investment advice. Both NBIX and PME.AX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is NBIX better than PME.AX for value investing?

On the Buffett-style value-investing framework, PME.AX currently grades higher — 78/100 vs 66/100, a 12-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between NBIX and PME.AX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). NBIX currently scores 66/100 (B grade); PME.AX scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, NBIX or PME.AX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. NBIX and PME.AX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, NBIX or PME.AX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are NBIX and PME.AX both Healthcare stocks?

Yes — both Neurocrine Biosciences, Inc. (NBIX) and Pro Medicus Limited (PME.AX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this NBIX vs PME.AX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Neurocrine Biosciences

NBIX$18BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$18.81BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

NBIX 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

NBIX0wins

7winsPME.AX

Warren Buffett

66C

B78

Benjamin Graham

76B

A90

Philip Fisher

78B

A98

Peter Lynch

63C

A100

Joel Greenblatt

53D

B84

Charlie Munger

58D

A91

Terry Smith

61C

A96

Side-by-side metrics

Metric	NBIX	PME.AX
Market cap	$18B	$18.81B Winner
P/E (TTM)	Winner: 22.6x	147.6x
EV/EBIT	Winner: 24.7x	106.8x
ROIC (TTM)	13.68%	42.56% Winner
Gross margin	98.17%	99.85% Winner
Net margin	21.55%	54.12% Winner
Revenue CAGR 5y	26.04%	31.61% Winner
EPS CAGR 5y	Winner: 50.0%	37.34%
Debt / Equity	0.1x	0.0x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

NBIX leads on

P/E (TTM)22.6xvs 147.6x+85%
EV/EBIT24.7xvs 106.8x+77%
EPS CAGR 5y50.0%vs 37.34%+25%

PME.AX leads on

Debt / Equity0.0xvs 0.1x+93%
ROIC (TTM)42.56%vs 13.68%+68%
Net margin54.12%vs 21.55%+60%
Revenue CAGR 5y31.61%vs 26.04%+18%

More like NBIX

NBIX vs JSLL.BO NBIX vs JSLL.NS NBIX vs 4728.TWO NBIX vs 1681.HK

More like PME.AX

PME.AX vs JSLL.BO PME.AX vs JSLL.NS PME.AX vs 4728.TWO PME.AX vs 1681.HK

Read the full Buffett-Brain analysis for NBIX Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Neurocrine Biosciences

NBIX$18BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$18.81BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

NBIX 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

NBIX0wins

7winsPME.AX

Warren Buffett

66C

B78

Benjamin Graham

76B

A90

Philip Fisher

78B

A98

Peter Lynch

63C

A100

Joel Greenblatt

53D

B84

Charlie Munger

58D

A91

Terry Smith

61C

A96

Side-by-side metrics

Metric	NBIX	PME.AX
Market cap	$18B	$18.81B Winner
P/E (TTM)	Winner: 22.6x	147.6x
EV/EBIT	Winner: 24.7x	106.8x
ROIC (TTM)	13.68%	42.56% Winner
Gross margin	98.17%	99.85% Winner
Net margin	21.55%	54.12% Winner
Revenue CAGR 5y	26.04%	31.61% Winner
EPS CAGR 5y	Winner: 50.0%	37.34%
Debt / Equity	0.1x	0.0x Winner
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

NBIX leads on

P/E (TTM)22.6xvs 147.6x+85%
EV/EBIT24.7xvs 106.8x+77%
EPS CAGR 5y50.0%vs 37.34%+25%

PME.AX leads on

Debt / Equity0.0xvs 0.1x+93%
ROIC (TTM)42.56%vs 13.68%+68%
Net margin54.12%vs 21.55%+60%
Revenue CAGR 5y31.61%vs 26.04%+18%

More like NBIX

NBIX vs JSLL.BO NBIX vs JSLL.NS NBIX vs 4728.TWO NBIX vs 1681.HK

More like PME.AX

PME.AX vs JSLL.BO PME.AX vs JSLL.NS PME.AX vs 4728.TWO PME.AX vs 1681.HK

Read the full Buffett-Brain analysis for NBIX Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.